ClinicalTrials.gg
RecruitingNCT07110324PAIN-COMPOUpdated Apr 1, 2026

Characteristics of Persistent Pain Composition Following Total Hip or Knee Arthroplasty: a Descriptive Study

An observational study in Pain (Visceral, Somatic, or Neuropathic), Hip Arthroplasty Replacement and Knee Arthroplasty, Total, sponsored by Rigshospitalet, Denmark. Recruiting at 1 site in Denmark. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-04-01.

Sponsored by Rigshospitalet, Denmark · Observational

How we know

From the registry’s dates

  • Started Jun 2025; still recruiting 1 year 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
100
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 28 studies in Pain by Rigshospitalet, Denmark — 2 open to participants now, 2 under way, none of them phase 3. Pain · Rigshospitalet, Denmark.

Planned enrollment
5th of 11
100 · median 82
Started
2025
with 2 others
Observational
11 of 28
1 open now
Registered
27th of 28
by date

Among the 28 studies in Pain by Rigshospitalet, Denmark, this one is the 5th largest by planned enrollment of the 11 observational ones that give a count, is one of 3 that started in 2025, is one of 11 observational ones, and was the 27th registered.

Pain

10,076 studies on the registry are indexed under Pain; 1,648 are open to participants now.

Browse Pain studies →

Open to participants now

2 of the 28 studies in Pain by Rigshospitalet, Denmark are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Where they have run

Who these studies take

Of the 930 Pain studies recruiting now, 384 (41%) set no upper age limit and 434 (47%) stop at 75 or younger; 146 take children under 18; 220 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 28 studies in Pain by Rigshospitalet, Denmark, or all of them as a file.
02

Study summary

Despite high success rates of hip and knee arthroplasty, up to 20% of patients report moderate-to-severe pain (NRS > 3) persisting beyond the expected healing period. This investigator-initiated, descriptive cohort study will re-invite approximately 100 consenting patients with persistent postoperative pain-identified from a pool of \~7 000 respondents-to complete standardized assessments of neuropathic (DN4), nociplastic (IASP criteria + Fibromyalgia Survey Questionnaire) and nociceptive (KOOS/HOOS pain domains) pain. Primary outcomes are the prevalence of potential nociplastic pain and the proportion experiencing significant pain in two or more mechanistic categories. Secondary analyses will compare baseline vs. re-evaluated DN4 scores, FSQ and KOOS/HOOS distributions, and examine differences between patients with and without possible neuropathic pain. Findings will inform targeted pre- and postoperative pain management strategies.

Read the detailed description

Introduction Background: Knee and hip arthroplasties are primarily performed due to degenerative changes that typically result in pain, functional impairment, and a subsequent decline in quality of life [1]. Arthroplasty represents the definitive intervention, involving the removal of the degenerated, pain-inducing joint components and their replacement with artificial prostheses. These procedures are considered standard in orthopedic surgery, boasting high success rates and high levels of patient satisfaction [2,3,4]. Nevertheless, the surgeries are not without risks, including perioperative complications such as infection, thrombosis, and prosthetic dislocation. Additionally, the economic burden on healthcare systems is considerable, encompassing not only the costs of the surgery itself but also postoperative care and rehabilitation. Hence, it is essential that the procedure yields the desired pain-relieving and functional outcomes to justify its use. Osteoarthritis is the primary indication for arthroplasty, representing a leading cause of disability worldwide. In advanced stages of osteoarthritis, the pain profile can become multifaceted, often involving a combination of nociceptive, neuropathic, and nociplastic pain mechanisms. Nociceptive pain, stemming from joint tissue damage and inflammation, is the most prevalent form and is usually effectively managed by arthroplasty. However, the complexity of pain perception in osteoarthritis extends beyond the joint, potentially involving altered pain processing pathways within the central and peripheral nervous systems. Up to 20% of patients report significant persistent pain following arthroplasty despite uncomplicated surgery and no apparent source of pain. This could be explained by the presence of non-nociceptive pain. Neuropathic pain stem from nerve damage, while nociplastic pain is associated with altered central pain processing, leading to pain persisting even after the natural healing process [5]. Identifying the type of pain in patients with persistent post-surgical pain could have important implications for pre-surgical as well as post-surgical management.

Objective: The aim of this study is to explore the pain composition in terms of neuropathic, nociceptive and nociplastic pain in patients with persistent pain after total knee arthroplasty (TKA), total hip arthroplasty (THA), or unicompartmental knee arthroplasty (UKA).

Hypotheses: The investigators hypothesize that postoperative pain with multiple pain types is prevalent and that neuropathic and nociplastic pain is co-existent or conflated in a considerable proportion of patients. Thus, there is an increased prevalence of potential nociplastic pain among patients with a Neuropathic Pain score (DN4) reflecting 'possible neuropathic pain'.

Perspective: Correct identification of pain types has important implications for pain management pre-operatively, peri-operatively, and post-operatively. Moreover, a high proportion of patients with potential nociplastic pain could increase the focus on the link between preoperative patient characteristics and post-operative potential nociplastic pain. This would help targeting those individuals benefiting most from operation compared to non-surgical management. Although results from this post-operative population do not necessarily reflect the prevailing pre-operative pain composition, the results from the study can potentially form the basis for hypothesis testing in a pre-operative cohort.

Methods This protocol was registered before initiation of data collection.

Study design Descriptive Cohort Study: Approximately 7,000 patients have been administered questionnaires to indicate persistent postoperative pain including the DN4 questionnaire to indicate potential neuropathic pain [6]. All patients with evidence of persistent pain following operation and have consented to be contacted, will receive invitation to participate in the study to complete new patient-reported outcome measures (PROMs). For comparison in pain composition between patients with and without possible neuropathic pain, the investigators expect to include 100 patients with possible neuropathic pain, as around 6% of the 7,000 (with 25% consenting to be contacted) scored high enough to consider possible neuropathic pain.

Variables The DN4 will be administered again to assess any development. Nociplastic pain will be evaluated based on the International Association for the Study of Pain (IASP) criteria and using the Fibromyalgia Survey Questionnaire (FSQ), and nociceptive pain will be measured through Knee injury and Osteoarthritis Outcome Pain Domain Score (KOOS) / Hip Disability and Osteoarthritis Outcome Score (HOOS). Patients will also be asked about their satisfaction with the outcome and their thoughts on potential re-operation.

Outcomes

  • Primary outcomes: Prevalence of potential nociplastic pain (defined by IASP criteria) and proportion of patients with significant painscores in two or more pain categories.
  • Secondary outcomes:

    1. Difference between baseline and re-evaluated DN4i (DN4 interview) score.
    2. Prevalence of potential nociplastic pain, as assessed with the FSQ score.
    3. Distribution of KOOS/HOOS score.
    4. Difference in pain distribution in terms of IASP, FSQ, KOOS / HOOS in patients with possible neuropathic pain (DN4 score above 3) and patients without any kind of neuropathic pain (DN4 score equal to zero). (Substudy)
  • Exploratory: The investigators explore rates of satisfaction and consideration of re-operation.

Inclusion and exclusion criteria:

Inclusion criteria: All patients with persistent moderate-severe pain (NRS>3) after THA, TKA and UKA and acceptance to be contacted.

Exclusion criteria: Re-operation or luxation, do not want to be contacted, post-operative complications such as prosthesis infection, thromboembolism or fracture of the prosthesis.

Questionnaires

The questionnaire is a combination of following questionnaires (Appendix A):

  • DN4: To assess the presence of neuropathic pain, the DN4 questionnaire will be administered. This tool evaluates symptoms and characteristics of pain that may indicate neuropathic origins [7].
  • Nociplastic Pain Assessment: Based on the new IASP diagnostic criteria for complex regional pain syndrome (CRPS) (aka "the Budapest Criteria), patients will be assessed for nociplastic pain, which involves pain arising from altered pain processing [8].
  • KOOS/HOOS: The pain domain of the Knee Injury and Osteoarthritis Outcome Score (KOOS) and the Hip Disability and Osteoarthritis Outcome Score (HOOS) will be used to measure nociceptive pain and overall functional outcomes in the knee and hip joints, respectively ([9,10]. Scores ranges from 100 (equal to no pain) 0 (extreme pain). A score equal to or below 60 is considered significant.
  • Fibromyalgia Survey Questionnaire (FSQ): This questionnaire will also be used to identify symptoms consistent with nociplastic pain, which can mimic or coexist with postoperative pain [11]. A score equal to or greater than 13 points is consistent with a diagnosis of fibromyalgia, the most common nociplastic pain condition.
  • Satisfaction and re-operation: Patients will be queried about their satisfaction with the surgical outcome and their thoughts on the possibility of undergoing additional surgical interventions.

Statistical considerations

Descriptive cohort study. As such, no formal power calculation is conducted and the sample size depends on response rate form an pre-defined cohort. All statistical analyses will be conducted by using R statistical software version 4.1.1 (R Foundation for Statistical Computing, Vienna, Austria). within RStudio (version 1.4.1717). A two-tailed P \< 0.05 will be considered statistically significant. Data will be reported as mean (standard deviation (SD)) and mean difference (95% confidence interval (95% CI): lower limit (LL), upper limit (UL)).

References:

  1. Wiklund I, Romanus B. A comparison of quality of life before and after arthroplasty in patients who had arthrosis of the hip joint. J Bone Joint Surg Am. 1991 Jun;73(5):765-9. PMID: 2045402.
  2. Papakostidou I, Dailiana ZH, Papapolychroniou T, Liaropoulos L, Zintzaras E, Karachalios TS, Malizos KN. Factors affecting the quality of life after total knee arthroplasties: a prospective study. BMC Musculoskelet Disord. 2012 Jun 29;13:116. doi: 10.1186/1471-2474-13-116. PMID: 22748117; PMCID: PMC3476961.
  3. Snell DL, Dunn JA, Hooper G. Associations between pain, function and quality of life after total hip arthroplasty. Int J Orthop Trauma Nurs. 2024 Aug;54:101121. doi: 10.1016/j.ijotn.2024.101121. Epub 2024 Jul 14. PMID: 39029151.
  4. Shapira J, Chen SL, Rosinsky PJ, Maldonado DR, Lall AC, Domb BG. Outcomes of outpatient total hip arthroplasty: a systematic review. HIP International. 2021;31(1):4-11. doi:10.1177/1120700020911639
  5. Soni A, Wanigasekera V, Mezue M, Cooper C, Javaid MK, Price AJ, Tracey I. Central Sensitization in Knee Osteoarthritis: Relating Presurgical Brainstem Neuroimaging and PainDETECT-Based Patient Stratification to Arthroplasty Outcome. Arthritis Rheumatol. 2019 Apr;71(4):550-560. doi: 10.1002/art.40749. Epub 2019 Mar 6. PMID: 30295432; PMCID: PMC6430421.
  6. Bennett, M. I., Attal, N., Backonja, M. M., Baron, R., Bouhassira, D., Freynhagen, R., Scholz, J., Tölle, T. R., Wittchen, H. U., \& Jensen, T. S. (2007). Using screening tools to identify neuropathic pain. Pain, 127(3), 199-203.
  7. Spallone, V., Morganti, R., D'Amato, C., Greco, C., Cacciotti, L., \& Marfia, G. A. (2012). Validation of DN4 as a screening tool for neuropathic pain in painful diabetic polyneuropathy. Diabetic medicine : a journal of the British Diabetic Association, 29(5), 578-585.
  8. Goebel A, Birklein F, Brunner F, Clark JD, Gierthmühlen J, Harden N, Huygen F, Knudsen L, McCabe C, Lewis J, Maihöfner C, Magerl W, Moseley GL, Terkelsen A, Thomassen I, Bruehl S. The Valencia consensus-based adaptation of the IASP complex regional pain syndrome diagnostic criteria. Pain. 2021 Sep 1;162(9):2346-2348.
  9. Roos EM, Lohmander LS. The Knee injury and Osteoarthritis Outcome Score (KOOS): from joint injury to osteoarthritis. Health Qual Life Outcomes. 2003 Nov 3;1:64.
  10. Nilsdotter, A. K., Lohmander, L. S., Klässbo, M., \& Roos, E. M. (2003). Hip disability and osteoarthritis outcome score (HOOS)--validity and responsiveness in total hip replacement. BMC musculoskeletal disorders, 4, 10.
  11. Häuser, W., Jung, E., Erbslöh-Möller, B., Gesmann, M., Kühn-Becker, H., Petermann, F., Langhorst, J., Weiss, T., Winkelmann, A., \& Wolfe, F. (2012). Validation of the Fibromyalgia Survey Questionnaire within a cross-sectional survey. PloS one, 7(5), e37504. https://doi.org/10.1371/journal.pone.0037504
03

Conditions studied

  • Pain (Visceral, Somatic, or Neuropathic)
  • Hip Arthroplasty Replacement
  • Knee Arthroplasty, Total
  • Survey and Questionnaire

Browse trials for

Keywords

  • Pain
  • hip arthroplasty
  • knee arthroplasty
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Descriptive Cohort Study: Approximately 7,000 patients have been administered questionnaires to indicate persistent postoperative pain including the DN4 questionnaire to indicate potential neuropathic pain [6]. All patients with evidence of persistent pain following operation and have consented to be contacted, will receive invitation to participate in the study to complete new patient-reported outcome measures (PROMs). For comparison in pain composition between patients with and without possible neuropathic pain, we expect to include 100 patients with possible neuropathic pain, as around 6% of the 7,000 (with 25% consenting to be contacted) scored high enough to consider possible neuropathic pain.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • All patients with persistent moderate-severe pain (NRS>3) after THA, TKA and UKA
  • Acceptance to be contacted.

Exclusion criteria

Exclusion Criteria:

  • Re-operation
  • Luxation
  • Do not want to be contacted
  • Post-operative complications such as prosthesis infection, thromboembolism or fracture of the prosthesis.
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
100 participants (estimated)
Target follow-up
1 Year
Patient registry
Yes

Groups and cohorts

  • Persistant pain (NRS above 3)

    Explore the pain composition in terms of neuropathic, nociceptive and nociplastic pain in patients with persistent pain after total knee arthroplasty (TKA), total hip arthroplasty (THA), or unicompartmental knee arthroplasty (UKA).

06

What researchers measure

Primary outcomes

  1. Potential nociplastic pain

    Prevalence of potential nociplastic pain (defined by International Association for the Study of Pain criteria)

    Time frame: 1 year

Secondary outcomes

  1. Difference between baseline and re-evaluated neuropathic pain score.

    Difference between baseline and re-evaluated neuropathic pain score.

    Time frame: 1 year

  2. Prevalence of potential nociplastic pain, as assessed with the Fibromyalgia Survey Questionnaire score.

    Prevalence of potential nociplastic pain, as assessed with the Fibromyalgia Survey Questionnaire score.

    Time frame: 1 year

  3. Distribution of Knee injury and Osteoarthritis Outcome Score (KOOS)

    Distribution of Knee injury and Osteoarthritis Outcome Score (KOOS)

    Time frame: 1 year

  4. Distribution of Hip injury and Osteoarthritis Outcome Score (HOOS)

    Distribution of Hip injury and Osteoarthritis Outcome Score (HOOS)

    Time frame: 1 year

Other outcomes

  1. Difference in pain distribution in terms of International Association for the Study of Pain score in patients with possible neuropathic pain (neuropathic pain score above 3) and patients without any kind of neuropathic pain (score equal to zero).

    Difference in pain distribution in terms of International Association for the Study of Pain score in patients with possible neuropathic pain (neuropathic pain score above 3) and patients without any kind of neuropathic pain (score equal to zero).

    Time frame: 1 year

  2. Rates of satisfaction

    Rates of satisfaction

    Time frame: 1 year

  3. Rates of consideration of re-operation.

    Rates of consideration of re-operation.

    Time frame: 1 year

  4. Difference in pain distribution in terms of Fibromyalgia Survey Questionnaire score in patients with possible neuropathic pain (neuropathic pain score above 3) and patients without any kind of neuropathic pain (score equal to zero).

    Difference in pain distribution in terms of Fibromyalgia Survey Questionnaire score in patients with possible neuropathic pain (neuropathic pain score above 3) and patients without any kind of neuropathic pain (score equal to zero).

    Time frame: 1 year

  5. Difference in pain distribution in terms of Knee injury and Osteoarthritis Outcome Score (KOOS) in patients with possible neuropathic pain (neuropathic pain score above 3) and patients without any kind of neuropathic pain (score equal to zero).

    Difference in pain distribution in terms of Knee injury and Osteoarthritis Outcome Score (KOOS) in patients with possible neuropathic pain (neuropathic pain score above 3) and patients without any kind of neuropathic pain (score equal to zero).

    Time frame: 1 year

  6. Difference in pain distribution in terms of Hip injury and Osteoarthritis Outcome Score (HOOS) in patients with possible neuropathic pain (neuropathic pain score above 3) and patients without any kind of neuropathic pain (score equal to zero).

    Difference in pain distribution in terms of Hip injury and Osteoarthritis Outcome Score (HOOS) in patients with possible neuropathic pain (neuropathic pain score above 3) and patients without any kind of neuropathic pain (score equal to zero).

    Time frame: 1 year

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2025 (actual). Primary completion is estimated for Dec 2026, 17 months after the start.

Of 505 non-industry observational studies under Pain, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 42. This study's planned 17 months is below that.

Counting every sponsor, half of 520 studies reached it within 18 months; a quarter within 8 and three quarters within 41.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 26, 2025
First posted
Aug 7, 2025
StartActual
Jun 26, 2025
Primary completionEst.
Dec 1, 2026
CompletionEst.
Dec 1, 2026
Last update
Apr 1, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 1, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07110324
Collaborators
Bispebjerg Hospital
Responsible party
Milan Mohammad (Principal Investigator, Rigshospitalet, Denmark) — Principal investigator
First posted
Aug 7, 2025
Start date
Jun 26, 2025
Primary completion
Dec 1, 2026 (estimated)
Completion
Dec 1, 2026 (estimated)
Last update
Apr 1, 2026

Study contacts

Milan Mohammad, MD
Contact
milanmohammad@hotmail.com
+4560162372

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion